Biotech Investment & Fundraising Advisory

Strategic, scientific, and operational expertise to support life science investors, guide biotech fundraising, and accelerate value across the investment lifecycle.

Alacrita provides hands-on advisory and execution support to life science investors, their portfolio companies, and directly to early-stage biotechs. Our consultants bring deep scientific, strategic, and operational expertise, from due diligence and opportunity assessment to post-investment execution, fundraising strategy, and investor communications. We also supplement in-house and external IR efforts with scientific and strategic depth, enabling teams to engage the investment community with clarity and credibility.

We help biotech teams prepare for financing, sharpen value positioning, and deliver on development milestones, while giving investors the insight, clarity, and bandwidth needed to guide value creation. Whether you're evaluating a new opportunity or helping a portfolio company deliver on its investment thesis, we’re here to help ensure success at every stage.

Recent Projects

The below selection of recent projects can help illustrate the type of support we typically provide to investors:

• Investor due diligence on clinical stage oncology therapeutic company: A VC investor asked Alacrita to conduct due diligence on a clinical stage oncology therapeutic company developing a targeted inhibitor that works via the notch pathway. Priority indications included rare oncology (solid and liquid) indications, and a biomarker approach was being pursued which required a companion diagnostic to be developed, to ensure targeting of the drug to the appropriate patients. Before the client made a commitment to invest in the oncology company, it wanted some external due diligence.
  
  
• Strategic Board Observation and Valuation Support for Private Equity in Regenerative Medicine: Alacrita supported a private equity investor by serving as a board observer for a regenerative medicine company, providing strategic insight, valuation expertise, and operational oversight. The engagement included updating prior due diligence, conducting a tailored valuation using limited comparables and DCF analysis, and identifying key milestones likely to drive value over 12–24 months, helping inform the investor’s exit strategy and enhance governance.
  
  
• Valuation of a drug discovery company with Monte Carlo simulation: A drug discovery company preparing for a forthcoming funding round wanted to update a valuation of the business based on a series of contract research projects and the proprietary value in its other research collaborations, and to understand which projects would maximize longer term value.
  
  
• Providing due diligence to a major pension fund for an Alzheimer’s treatment: Our client, a major pension fund, was considering an investment in a Phase III neuroscience company, which was developing a small molecule to provide symptomatic relief of Alzheimer’s Disease (AD). Our client wanted to know the likelihood of clinical success in an ongoing Phase III clinical trial, therefore, one of our neuroscience consultants was selected to provide expert advice.
  
  

• Due diligence on a novel T cell therapy and discovery platform for a VC: A VC investor wished to make an investment in a California-based preclinical biotechnology company with a discovery platform and novel T cell therapies for cancer and other diseases and required a technical due diligence on the company. 

• Evaluation of Phase III probability of success for a private equity fund: A private equity fund approaching an investment in a Phase III asset required an expert evaluation of the likelihood of success in the Phase III trial. The molecule, targeted at two CNS indications, had been extensively tested in Phase II and an inconclusive Phase III study, and the investor needed to understand whether the rationale and current understanding of the product, taken together with the totality of data developed to date, provided sufficient support for investing in a further pivotal trial.
  
  

Related White Papers:

• Valuing Pharmaceutical Assets: When to Use NPV vs rNPV

• Pharma Due Diligence: General Guidance & Common Pitfalls

• Pharmaceutical Probability of Success